

## DIASORIN S.P.A. – UPDATE 2023 ANNUAL CALENDAR OF CORPORATE EVENTS\*

**Saluggia, February 7, 2023** – Partially updating the notice submitted on December 1, 2022, please find below the annual calendar of corporate events, including the new scheduled date for approval of the Draft Statutory Financial Statements 2022 and Consolidated Financial Statements 2022.

### **Board of Directors**

<b>March 27, 2023</b>	<b>Draft Statutory Financial Statements 2022 and Consolidated Financial Statements 2022</b> approval
<b>May 12, 2023</b>	<b>First Quarter 2023 results</b> approval
<b>July 27, 2023</b>	<b>Half-Yearly Financial Report</b> approval
<b>November 10, 2023</b>	<b>Third Quarter 2023 results</b> approval

### **Shareholders' Meeting**

<b>April 28, 2023</b>	<b>Annual General Meeting</b> for: (i) Statutory Financial Statements 2022 approval; (ii) Report on the remuneration policy and fees paid approval.
-----------------------	---

\* Indicative dates subject to change. Any changes will be communicated without delay.

In addition, the Company notifies that the month envisaged for the payment of any dividend in relation to 2022 results is May 2023. The information herein reported is given for the exclusive purpose of complying with the relevant Borsa Italiana S.p.A. regulations and cannot be interpreted or considered in any way as a forecast on the occurrence of the requirements for the distribution of dividends.

### **For additional information, please contact:**

**Riccardo Fava**  
*Corporate Vice President Communication & Investor Relations*  
 Tel: +39.0161.487988  
[riccardo.fava@diasorin.it](mailto:riccardo.fava@diasorin.it)

### **About DiaSorin**

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide. The Group operates in 5 continents through 41 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions DiaSorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist". More info at [www.diasoringroup.com](http://www.diasoringroup.com)